Investment Rating - The report maintains a "Buy" rating for China Resources Beer (291.HK) with a target price of HKD 31.0 per share, indicating a potential upside of 22.1% from the current price of HKD 25.38 [1][5][13]. Core Insights - The company's revenue for 2025 is projected at HKD 379.85 billion, reflecting a year-on-year decline of 1.68%, primarily due to the underperformance of its liquor business. The net profit attributable to shareholders is expected to be HKD 33.71 billion, down 28.87% year-on-year, largely impacted by a liquor impairment of HKD 28.77 billion. Excluding this impairment, the adjusted net profit would be HKD 57.24 billion, representing a growth of 19.6% [3][8]. - The beer segment shows resilience, with revenue remaining stable at HKD 382.57 billion and beer sales increasing by 1.4% to 11.03 million tons. The company's high-end strategy continues to drive growth, with premium and above beer sales rising nearly 10% [3][9]. - The liquor business faced significant challenges, with revenue dropping 30.39% to HKD 14.96 billion. The company has recognized an impairment of HKD 28.77 billion for goodwill in this segment, but the EBITDA for the liquor business, excluding this impairment, is HKD 2.64 billion [5][12]. Summary by Sections Financial Performance - In 2025, the company achieved a revenue of HKD 379.85 billion, a slight decrease of 1.68% year-on-year. The net profit attributable to shareholders was HKD 33.71 billion, down 28.87% due to the liquor impairment. Adjusted net profit, excluding the impairment, was HKD 57.24 billion, up 19.6% [3][8]. - The gross margin improved to 43.1%, benefiting from cost savings and product mix optimization, while adjusted EBITDA reached HKD 96.11 billion, a 17.4% increase [8][9]. Business Strategy - The company is committed to its high-end strategy in the beer segment, which has shown resilience against industry challenges. The focus on premium products is expected to continue driving growth, with plans to enhance craft beer production and expand into international markets [9][12]. - In response to the liquor market's difficulties, the company is actively seeking to optimize its operations, including expanding wholesale channels and improving organizational efficiency [5][12]. Future Outlook - The report forecasts net profits for 2026-2028 to be HKD 58.95 billion, HKD 63.62 billion, and HKD 68.44 billion, respectively, indicating growth rates of 74.9%, 7.9%, and 7.6% year-on-year [6][13].

Investment Rating - The report suggests a positive outlook for the company, indicating that it is significantly undervalued with a market capitalization of only 2.7 billion HKD, and recommends active monitoring of the stock [9]. Core Insights - The company achieved a total revenue of 0.29 billion RMB for the fiscal year 2025, representing a year-on-year growth of 1344.77%, while net losses narrowed by 43.27% to 1.05 billion RMB [1]. - Cost control measures have been effective, with administrative expenses reduced by 16.4 million RMB and R&D costs optimized, particularly focusing on the SM17 clinical trials [2]. - The clinical development of SM17 is progressing rapidly, with promising results in the 1b phase study for atopic dermatitis, showing a 91.7% itch relief rate and 75% achieving skin lesion recovery [3]. - The company is building a differentiated pipeline in autoimmune diseases, with potential for significant business development (BD) opportunities as clinical trials advance [4]. Summary by Sections Financial Performance - Total revenue for 2025 reached 0.29 billion RMB, a substantial increase of 1344.77% year-on-year, while net losses decreased to 1.05 billion RMB, a reduction of 43.27% compared to the previous year [1]. Cost Management - The company has effectively controlled costs, reducing administrative expenses by 16.4 million RMB and optimizing R&D costs, particularly in the SM17 clinical program [2]. Clinical Development - SM17 is advancing quickly in clinical trials, with a 2nd phase study for atopic dermatitis expected to start in mid-2026, and positive results from the 1b phase study indicating high efficacy and safety compared to existing treatments [3]. Pipeline and Strategic Focus - The company is focused on developing first-in-class (FIC) and best-in-class (BIC) therapies, with a rich pipeline in autoimmune diseases and plans for significant BD opportunities as key data is released in 2026-2027 [4].

Investment Rating - The report assigns a positive investment rating to Zijin Mining International (2259.HK), highlighting its strong performance and growth potential in the gold mining sector [6]. Core Insights - The company achieved significant growth in 2025, with revenue reaching approximately $5.38 billion, a substantial increase of 80% year-on-year. Net profit attributable to shareholders surged to about $1.6 billion, marking a 233% increase. Free cash flow also saw a remarkable rise of 359%, totaling approximately $1.79 billion [1][2]. - The company’s operational strategy of combining technological upgrades and acquisitions has proven effective, with a focus on enhancing production capacity and integrating newly acquired assets [3][5]. Summary by Relevant Sections Financial Performance - In 2025, Zijin Mining produced 46.9 tons of gold, a 20% increase from 2024. The average selling price of gold reached $3,524 per ounce. The all-in sustaining cost (AISC) was maintained at $1,501 per ounce, a slight increase of 3% from the previous year [2][3]. - Cash and cash equivalents at the end of 2025 were approximately $3.62 billion, with net cash inflow from operating activities around $2.4 billion [2]. Growth Strategy - The company invested approximately $2 billion in acquiring the Akyem and Raygorodok gold mines, which contributed about $800 million in revenue and $290 million in profit. The AISC for Akyem was approximately $1,719 per ounce, while Raygorodok's AISC was about $1,249 per ounce [3][5]. - Future production guidance indicates a total gold output of approximately 59.2 tons in 2026, with a target of 70-75 tons by 2028. The company also plans to acquire Allied Gold Corporation for about $4 billion, which will enhance its presence in West Africa [5][6]. Operational Efficiency - The company’s strategy of internal growth through technological upgrades is expected to significantly increase production capacity at existing mines. For instance, the Akyem mine's processing capacity may reach 13 million tons per year [5]. - The debt-to-equity ratio improved from 46% to 29%, reflecting a stronger financial position and operational efficiency [6].

Investment Rating - The report suggests a cautious subscription for the company, Huayan Robotics, with an IPO price of HKD 17 per share, corresponding to a PS of 25.6 times for 2024, which is in the middle range of the industry [3]. Core Insights - The company specializes in collaborative robots for industrial automation applications, with a projected global market revenue of RMB 7.5 billion for collaborative robots by 2024, representing approximately 1.7% of the total global robot market revenue of RMB 431.6 billion [2]. - The global robot market is expected to grow from RMB 256 billion in 2020 to RMB 431.6 billion in 2024, with a compound annual growth rate (CAGR) of 14.0%. The market is anticipated to continue expanding at a CAGR of 15.0% from 2025 to 2029, reaching RMB 861.9 billion by 2029 [2]. - The company's revenue increased from RMB 1.094 billion in 2022 to RMB 1.754 billion in 2023, marking a 60.2% growth, and is projected to further increase by 77.0% to RMB 3.104 billion in 2024, resulting in a CAGR of 68.4% from 2022 to 2024. The company is expected to turn a profit by 2024, with a net profit of RMB 179 million, making it one of the few profitable companies in the global collaborative robot sector [3].

Investment Rating - The report suggests a cautious subscription for the company’s IPO [3]. Core Insights - The company is a global leader in the silicon carbide (SiC) epitaxy industry, focusing on the research, production, and sales of SiC epitaxial chips and components used in semiconductor devices [2]. - The company’s SiC epitaxial chips are utilized in power devices, which have widespread applications in electric vehicles, charging infrastructure, renewable energy, and energy storage systems [2]. - According to a report by ZhiShi Consulting, the company is the largest supplier of SiC epitaxy by sales volume since 2023, with a market share exceeding 30% in 2024 [2]. - The global market for SiC power semiconductor devices is projected to grow significantly, with sales increasing from USD 600 million in 2020 to USD 2.6 billion in 2024, representing a compound annual growth rate (CAGR) of 45.4% [2]. - By 2029, the sales of SiC power semiconductor devices are expected to reach USD 13.6 billion, with a CAGR of 39.9% from 2024 to 2029 [2]. - The penetration rate of SiC power semiconductor devices in the global power semiconductor market is anticipated to rise from 1.3% in 2020 to 4.9% in 2024, and further to 17.1% by 2029 [2]. Financial Performance - The company's revenue for the years 2022, 2023, and 2024, as well as for the nine months ending September 30, 2024, are projected to be RMB 440.7 million, RMB 1,142.5 million, RMB 974.3 million, RMB 808.3 million, and RMB 535.1 million respectively [3]. - The net profit for the same periods is expected to be RMB 127.5 million, RMB 107.5 million, RMB 165.1 million, RMB 118.4 million, and RMB 21.1 million respectively [3]. - Starting in 2024, the company's financial performance is anticipated to be negatively impacted by competitive market pressures leading to price declines and weakened demand in downstream markets [3]. - The company's Hong Kong IPO price is set at HKD 76.26 per share, corresponding to a price-to-sales (PS) ratio of 29.3 times for 2024, which is considered to be in the middle range within the industry [3].

Investment Rating - The report suggests a cautious subscription for the company [1]. Core Insights - The company is a provider of AI visual solutions in China, ranking eighth in the emerging market for AI visual solutions based on revenue in 2024 [2]. - The business is divided into two segments: standard and customized AI visual solutions, and large model solutions utilizing advanced technologies for enterprise applications [2]. - The market for enterprise-level AI visual solutions in China is projected to grow from CNY 10.7 billion in 2020 to CNY 36.8 billion in 2024, and further to CNY 182.4 billion by 2029 [2]. - The global market for enterprise-level AI visual solutions is expected to reach CNY 149.6 billion in 2024 and CNY 505.2 billion by 2029, with a compound annual growth rate (CAGR) of 27.6% [2]. Financial Performance - The company has shown rapid growth, with revenue increasing from CNY 102 million in 2022 to CNY 257 million in 2024 [3]. - Adjusted losses decreased from CNY 52.9 million in 2022 to CNY 44.3 million in 2023, with a projected adjusted profit of CNY 20.5 million in 2024 [3]. - The estimated market capitalization post-IPO is approximately HKD 4.5 billion, with the IPO price corresponding to an adjusted net profit multiple of about 204 times for 2024 and a price-to-sales ratio of approximately 16 times, indicating a high valuation [3].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 5.78 per share, indicating an expected upside of 83.4% from the current price of HKD 3.15 [1][10][11]. Core Insights - The company's performance in 2025 met expectations, with revenue of approximately HKD 1.904 billion, a year-on-year increase of 72.8%, and a net profit of HKD 302 million, up 57.3% [3][7]. - The growth in performance is primarily attributed to the increase in the comprehensive quality education business, which saw a 106% year-on-year increase in class hours and a 2.5% increase in overall class prices [3][8]. - The company is leveraging AI to enhance its educational offerings, focusing on personalized teaching and operational efficiency, with products like AI Learning Companion and AI Reading being introduced [3][8]. Financial Performance - The gross margin for 2025 was 45.4%, a slight decline of 0.9 percentage points, influenced by factors such as new teacher recruitment and market competition [5][9]. - The company has a progressive dividend policy, with payout ratios expected to increase from 50% in 2024 to 70% in 2026, and a projected dividend yield exceeding 10% by 2026 [5][10]. - The projected net profit for 2026-2028 is expected to grow at rates of 12.0%, 12.8%, and 14.3%, respectively, with net profits estimated at HKD 338 million, HKD 381 million, and HKD 435 million [11].

Investment Rating - The report suggests a cautious subscription for the company’s IPO [1]. Core Insights - The company, established in 2016, focuses on developing medical imaging products and services, with a diverse product portfolio aimed at enhancing diagnostic efficiency and service quality [2]. - The core product, AI AutoVision®, is designed for chromosome karyotype analysis, targeting prenatal diagnosis and assisted reproductive diagnosis [2]. - The global market for chromosome karyotype analysis is projected to grow from USD 3.826 billion in 2019 to USD 6.588 billion by 2024, with a compound annual growth rate (CAGR) of 11.5% [3]. - The company’s revenue is expected to grow significantly, from RMB 52.844 million in 2023 to RMB 70.352 million in 2024, representing a year-on-year increase of 33.2% [4]. - Despite revenue growth, the company remains in a loss position, with losses narrowing from RMB 56.116 million in 2023 to RMB 43.375 million in 2024 [4]. - The estimated market capitalization post-IPO is between HKD 8.49 billion and HKD 9.99 billion, with a static price-to-sales (PS) ratio of 110 times, indicating a high valuation [4]. Industry Overview - The chromosome karyotype analysis market is expected to accelerate, reaching USD 15.33 billion by 2030 and further expanding to USD 50.467 billion by 2035, driven by the adoption of automated workstations [3].

Investment Rating - The report maintains a "Buy" rating for China Oriental Education with a target price of HKD 10.38 per share, indicating a potential upside of 73.3% from the current price of HKD 5.99 [7][15]. Core Insights - The company's performance is strong, with adjusted net profit at the upper limit of the earnings forecast. In 2025, revenue reached HKD 46.16 billion, a year-on-year increase of 12.1%, while net profit grew by 47.5% to HKD 7.56 billion. Adjusted net profit increased by 50.9% to HKD 7.92 billion [3][10]. - Growth is driven by an increase in training participants, higher average tuition fees, and continuous operational efficiency improvements. The company reported a 15% increase in overall enrollment, with significant growth in short-term training programs [10][12]. - All business segments showed growth, with the beauty industry maintaining a high growth rate of 71.7%. The average training participants and tuition fees also increased across various segments [11][12]. Financial Performance - In 2025, the company's gross margin was 55.3%, up 3.9 percentage points year-on-year, primarily due to revenue growth and cost efficiency. The net profit margin improved to 16.4%, reflecting a 3.9 percentage point increase [6][14]. - The company effectively managed its expenses, with sales, management, R&D, and financial expense ratios decreasing compared to the previous year [14]. - Forecasts for 2026-2028 predict revenue growth to HKD 53.27 billion, HKD 60.38 billion, and HKD 68.19 billion, with corresponding net profits of HKD 10.04 billion, HKD 12.57 billion, and HKD 14.83 billion, indicating robust growth prospects [8][15].

Investment Rating - The report suggests a cautious subscription for the company, Kales Technology (2729.HK) [2][3]. Core Insights - The company is a mature player in the intelligent in-house logistics robot industry, with a diverse portfolio of self-developed robotic products and a market share of 1.6% among the top five comprehensive intelligent in-house logistics robot companies in China as of 2024 [2]. - The global intelligent in-house logistics market is projected to grow from RMB 270.6 billion in 2020 to RMB 455.1 billion in 2024, with a compound annual growth rate (CAGR) of 13.7% from 2025 to 2030 [2]. - The intelligent logistics robot market is expected to increase from RMB 42.6 billion in 2020 to RMB 118.3 billion in 2024, with a CAGR of 19.4% from 2025 to 2030 [2]. Financial Performance - The company's total revenue for 2022, 2023, and 2024 was RMB 656.9 million, RMB 550.8 million, and RMB 721.4 million, respectively. The annual losses narrowed from RMB 209.6 million in 2022 and RMB 241.6 million in 2023 to RMB 178.1 million in 2024 [3]. - For the nine months ending September 30, 2024, the company reported a loss of RMB 141.3 million, which decreased to RMB 134.5 million in the same period for 2025 [3]. - The IPO price midpoint is set at HKD 18.4 per share, corresponding to a price-to-sales (P/S) ratio of 9.6 times for 2024 [3].